December 16, 2020 — The combination of nivolumab with ipilimumab demonstrated activity in patients with metastatic uveal melanoma with encouraging responses. Meredith Pelster, MD The combination of nivolumab (Opdivo) with ipilimumab (Yervoy) demonstrated activity in patients with metastatic uveal melano...
1.Wolchok JD, Chiarion-Sileni V, Gonzalez R, et al. Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. J Clin Oncol. 2022;40(2):127-137. 2.Lebbé C, Meyer N, Mortier L, e...
VanderWalde A, Moon J, Bellasea S, et al. Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy. Presented at: 2022 AACR Annual Meeting; April 8-13, 2022; New Orleans, LA. Abstract CT013.Recen...
and other cancers. Immune-mediated colitis is one of their adverse events thatneed to be differentiated from low-grade diarrhea as one of the most common side effects. A 51-year-oldwoman with relapsed metastatic melanoma presented with intractable diarrhea, nausea, vomiting, andgeneralized abdominal...
3. Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain.N Engl J Med. 2018;379(8):722-730. doi:10.1056/NEJMoa1805453
The addition of UV1 to nivolumab/ipilimumab failed to improve PFS in the frontline treatment of unresectable or metastatic melanoma. Melanoma | Image Credit: © SciePro - stock.adobe.com The addition of the universal cancer vaccine UV1 to the combination of nivolumab (Opdivo) and ipilimumab ...
Radiotherapy, Ipilimumab and Nivolumab in Metastatic Melanoma,Peter MacCallum Cancer Centre,Interventional,Phase 1/Phase 2
Intestinal hypomotility as irAEs is exceedingly rare, and needs wider recognition given that the presentation is insidious. Here, we report a case of 79-year-old woman with metastatic melanoma under nivolumab and ipilimumab combination therapy. She developed ileus symptom, and was diagnosed with ...
科研级Nivolumab生物类似药,抗人PD-1单克隆抗体(Nivolumab biosimilar, research grade, anti-human PD-1 monoclonal antibody) 科研级Pembrolizumab生物类似药,抗人PD-1单克隆抗体(Pembrolizumab biosimilar, research grade, anti-human PD-1 monoclonal antibody) ...
别名 Anti CTLA-4 monoclonal antibody、Anti-CTLA-4 Mab、Ipilimumab (Genetical Recombination) + [16] 靶点 CTLA4 作用机制 CTLA4抑制剂(细胞毒性T淋巴细胞相关抗原4抑制剂) 治疗领域 肿瘤消化系统疾病呼吸系统疾病+ [13] 在研适应症 不能切除的食管鳞状细胞癌食管癌间皮瘤+ [297] ...